- X-linked Chronic Granulomatous Disease
|
Donald Kohn |
University of California, Los Angeles |
Phase 1/2 |
Recruiting |
10 |
|
|
Douglas Losordo |
Caladrius Biosciences |
Phase 2 |
Active, not recruiting |
113 |
|
|
Howard Foyt |
ViaCyte, Inc. |
Phase 1/2 |
Active, not recruiting |
69 |
|
|
Howard Foyt |
ViaCyte, Inc. |
Phase 1/2 |
Recruiting |
55 |
|
|
Damien Bates |
SanBio, Inc. |
Phase 2 |
Active, not recruiting |
156 |
|
|
Jane Lebkowski |
Geron Corporation |
Phase 1 |
Completed |
5 |
|
|
Edward Wirth |
Asterias Biotherapeutics |
Phase 1/2 |
Completed |
25 |
|
|
Dennis Slamon |
University of California, Los Angeles |
Phase 1 |
Recruiting |
48 |
|
|
Joseph Rosenthal |
City of Hope, Beckman Research Institute |
Phase 1 |
Recruiting |
6 |
|
|
Donald Kohn |
University of California, Los Angeles |
Phase 1 |
Recruiting |
6 |
|
|
Stephen Gottschalk |
St. Jude Children's Research Hospital |
Phase 1/2 |
Recruiting |
28 |
|
|
Judith Shizuru |
Stanford University |
Phase 1/2 |
Recruiting |
90 |
|
- Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
|
Morton Cowan |
University of California, San Francisco |
Phase 1 |
Launching |
N/A |
|
|
Donald Kohn |
University of California, Los Angeles |
Phase 2 |
Active, not recruiting |
10 |
|
|
Henry Klassen |
University of California, Irvine |
Phase 1/2 |
Completed |
28 |
|
|
Henry Klassen |
jCyte, Inc |
Phase 2 |
Active, not recruiting |
84 |
|
|
Michael Lewis |
Cedars-Sinai Medical Center |
Phase 1/2 |
Recruiting |
26 |
|
|
Nancy Lane |
University of California, Davis |
Phase 1/2 |
Recruiting |
50 |
|
|
Kristen Johnson |
Calibr |
Phase 1 |
Recruiting |
60 |
|
|
Matthew Spear |
Poseida Therapeutics, Inc. |
Phase 1 |
Recruiting |
40 |
|
|
Robert Dillman |
Caladrius Biosciences |
Phase 3 |
Terminated |
250 |
|
|
Antoni Ribas |
University of California, Los Angeles |
Phase 1 |
Recruiting |
12 |
|
|
Steven Dubinett |
University of California, Los Angeles |
Phase 1 |
Launching |
N/A |
|
- Leukemia, Acute Myeloid (AML)
|
Colleen Delaney |
Nohla Therapeutics Inc |
Phase 2 |
Active, not recruiting |
146 |
|
- Leukemia, Acute Myeloid (AML)
|
Mark Chao |
Forty Seven Inc. |
Phase 1 |
Recruiting |
96 |
|
|
Jeffrey Lawson |
Humacyte, Inc. |
Phase 3 |
Active, not recruiting |
355 |
|
|
Samuel Strober |
Stanford University |
Phase 1 |
Active, not recruiting |
15 |
|
|
Jeffrey Lawson |
Humacyte, Inc. |
Phase 3 |
Recruiting |
240 |
|
|
Scott Batty |
Medeor Therapeutics, Inc. |
Phase 3 |
Recruiting |
75 |
|
|
Vicki Wheelock |
University of California, Davis |
Phase 1/2 |
Completed |
29 |
|
|
Geoff Symonds |
Calimmune, Inc. |
Phase 1/2 |
Completed |
12 |
|
|
John Zaia |
City of Hope, Beckman Research Institute |
Phase 1 |
Active, not recruiting |
12 |
|
|
Mehrdad Abedi |
University of California, Davis |
Phase 1/2 |
Recruiting |
18 |
|
|
Rachel Smith |
Capricor, Inc |
Phase 2 |
Active, not recruiting |
134 |
|
|
Linda Marban |
Capricor, Inc |
Phase 2 |
Completed |
25 |
|
|
Mark Chao |
Forty Seven Inc. |
Phase 1/2 |
Recruiting |
112 |
|
|
Anthony Gringeri |
ImmunoCellular Therapeutics |
Phase 3 |
Suspended |
414 |
|
|
Christine Brown |
City of Hope, Beckman Research Institute |
Phase 1 |
Recruiting |
92 |
|
|
Paul Finnegan |
Angiocrine Bioscience, Inc. |
Phase 1 |
Launching |
N/A |
|
|
Michael Pulsipher |
Children's Hospital of Los Angeles |
Phase 1/2 |
Launching |
N/A |
|
|
Edward Kavalerchik |
Angiocrine Bioscience, Inc. |
Phase 1 |
Launching |
N/A |
|
|
Thomas Kipps |
University of California, San Diego |
Phase 1 |
Active, not recruiting |
29 |
|
|
Irving Weissman |
Stanford University |
Phase 1 |
Completed |
88 |
|
|
Ed Conner |
Sangamo BioSciences, Inc. |
Phase 1/2 |
Recruiting |
6 |
|
|
Thomas Kipps |
University of California, San Diego |
Phase 1/2 |
Recruiting |
156 |
|
|
Crystal Mackall |
Stanford University |
Phase 1 |
Recruiting |
57 |
|
|
Ralph Kern |
BrainStorm Cell Therapeutics |
Phase 3 |
Recruiting |
200 |
|
|
Clive Svendsen |
Cedars-Sinai Medical Center |
Phase 1/2 |
Active, not recruiting |
18 |
|
|
Tippi MacKenzie |
University of California, San Francisco |
Phase 1 |
Recruiting |
10 |
|
|
Mark Humayun |
University of Southern California |
Phase 1 |
Active, not recruiting |
16 |
|